

This is a published notice on the Find a Tender service: <https://www.find-tender.service.gov.uk/Notice/007712-2025>

Tender

Provision of Community Pharmacy RSV and Pertussis Vaccination Enhanced Service

NHS England

F02: Contract notice

Notice identifier: 2025/S 000-007712

Procurement identifier (OCID): ocds-h6vhtk-04e916

Published 3 March 2025, 4:28pm

Section I: Contracting authority

I.1) Name and addresses

NHS England

7&8 Wellington Place

Leeds

LS1 4AP

Contact

Stacey Thrower

Email

stacey.thrower@nhs.net

Country

United Kingdom

Region code

UKE - Yorkshire and the Humber

Internet address(es)

Main address

<https://www.england.nhs.uk/>

Buyer's address

<https://www.england.nhs.uk/>

I.3) Communication

The procurement documents are available for unrestricted and full direct access, free of charge, at

<https://health-family.force.com/s/Welcome>

Additional information can be obtained from the above-mentioned address

Tenders or requests to participate must be submitted electronically via

<https://health-family.force.com/s/Welcome>

Tenders or requests to participate must be submitted to the above-mentioned address

Electronic communication requires the use of tools and devices that are not generally available. Unrestricted and full direct access to these tools and devices is possible, free of charge, at

<https://health-family.force.com/s/Welcome>

I.4) Type of the contracting authority

Body governed by public law

I.5) Main activity

Health

Section II: Object

II.1) Scope of the procurement

II.1.1) Title

Provision of Community Pharmacy RSV and Pertussis Vaccination Enhanced Service

Reference number

AG24034

II.1.2) Main CPV code

- 85100000 - Health services

II.1.3) Type of contract

Services

II.1.4) Short description

NHS Arden and Greater East Midlands Commissioning Support Unit (AGCSU) on behalf of NHS England (NHSE) (The Commissioner) would like to notify the market of an opportunity to provide Community Pharmacy RSV and Pertussis Vaccination Enhanced Service within the Midlands Region.

Respiratory Syncytial Virus (RSV) is a virus that for most people causes a mild respiratory illness, but can be more serious for those, including older adults and infants, who are at risk of more severe respiratory disease. Following the Joint Committee on Vaccination and Immunisation (JCVI) recommendation, the Commissioner will commission from September 2024:

- an adult programme (predominately to be commissioned through general practice); and
- an infant programme provided as vaccination during pregnancy (predominantly to be commissioned through NHS Trusts).

In addition, where there are areas of identified additional need, the Commissioner will commission community pharmacy to provide additional capacity and increased access to supplement the core provision of these two programmes.

Pertussis (whooping cough) is a respiratory disease that is caused by the *Bordetella pertussis* bacterium. Pertussis can cause serious and life-threatening complications including pneumonia, difficulty in breathing (apnoea) and seizures. Pertussis most commonly affects infants, and very young infants are at highest risk of serious

complications, of needing admission to hospital or of dying.

Pregnant women are eligible for the Pertussis vaccine from 16 weeks pregnancy, although the optimal window for protection is between 20 and 32 weeks of pregnancy. Commissioners have commissioned general practice and NHS trusts to deliver the Pertussis vaccination programme for pregnant women.

In addition, where there are areas of identified additional need, the Commissioner will commission community pharmacy to provide the Pertussis vaccination programme opportunistically to pregnant women to supplement the core service provision.

This Procurement Process is for the service provision in the Midlands Region where up to 66 sites from multiple potential Suppliers will be selected to provide the Services from May 2025. The 66 successful sites will be in three ICBs within the Midlands Region, with 22 sites allocated per lot to allow the Commissioner to ensure an even geographical spread. Should fewer than 22 sites be awarded to a Lot, up to 4 additional sites may be awarded under alternative Lot(s) at the Commissioners discretion. The ICB's included in this procurement are NHS Black Country ICB, NHS Leicester, Leicestershire, & Rutland ICB & NHS Birmingham and Solihull ICB.

The value of the service provision resulting from this Procurement Process will be an Item of Service (IoS) fee of £9.58 for the administration of each RSV and pertussis vaccine to each eligible patient.

The number of eligible patients, and therefore the likely activity level, could change as a result of factors beyond the Commissioner's control such as an increase or decrease in population of the local area, closure or merger of other nearby NHS health organisations, or patient.

Services will commence in May 2025 and will continue until 31st March 2027, with an option for the Commissioner to extend for 24 months until 31 March 2029.

Please note the deadline for responses to the ITT is 12:00PM (Mid-Day) on Friday 14th March 2025.

II.1.6) Information about lots

This contract is divided into lots: Yes

Tenders may be submitted for all lots

II.2) Description

II.2.1) Title

Lot 1: NHS Black Country ICB

Lot No

1

II.2.2) Additional CPV code(s)

- 85100000 - Health services

II.2.3) Place of performance

NUTS codes

- UKG - West Midlands (England)

II.2.4) Description of the procurement

NHS Arden and Greater East Midlands Commissioning Support Unit (AGCSU) on behalf of NHS England (NHSE) (The Commissioner) would like to notify the market of an opportunity to provide Community Pharmacy RSV and Pertussis Vaccination Enhanced Service within the Midlands Region.

Respiratory Syncytial Virus (RSV) is a virus that for most people causes a mild respiratory illness, but can be more serious for those, including older adults and infants, who are at risk of more severe respiratory disease. Following the Joint Committee on Vaccination and Immunisation (JCVI) recommendation, the Commissioner will commission from September 2024:

- an adult programme (predominately to be commissioned through general practice); and
- an infant programme provided as vaccination during pregnancy (predominantly to be commissioned through NHS Trusts).

In addition, where there are areas of identified additional need, the Commissioner will commission community pharmacy to provide additional capacity and increased access to supplement the core provision of these two programmes.

Pertussis (whooping cough) is a respiratory disease that is caused by the *Bordetella pertussis* bacterium. Pertussis can cause serious and life-threatening complications including pneumonia, difficulty in breathing (apnoea) and seizures. Pertussis most commonly affects infants, and very young infants are at highest risk of serious complications, of needing admission to hospital or of dying.

Pregnant women are eligible for the Pertussis vaccine from 16 weeks pregnancy, although the optimal window for protection is between 20 and 32 weeks of pregnancy.

Commissioners have commissioned general practice and NHS trusts to deliver the Pertussis vaccination programme for pregnant women.

In addition, where there are areas of identified additional need, the Commissioner will commission community pharmacy to provide the Pertussis vaccination programme opportunistically to pregnant women to supplement the core service provision.

This Procurement Process is for the service provision in the Midlands Region where up to 66 sites from multiple potential Suppliers will be selected to provide the Services from May 2025. The 66 successful sites will be in three ICBs within the Midlands Region, with 22 sites allocated per lot to allow the Commissioner to ensure an even geographical spread. Should fewer than 22 sites be awarded to a Lot, up to 4 additional sites may be awarded under alternative Lot(s) at the Commissioners discretion. The ICB's included in this procurement are NHS Black Country ICB, NHS Leicester, Leicestershire, & Rutland ICB & NHS Birmingham and Solihull ICB.

The value of the service provision resulting from this Procurement Process will be an Item of Service (IoS) fee of £9.58 for the administration of each RSV and pertussis vaccine to each eligible patient.

The number of eligible patients, and therefore the likely activity level, could change as a result of factors beyond the Commissioner's control such as an increase or decrease in population of the local area, closure or merger of other nearby NHS health organisations, or patient.

Services will commence in May 2025 and will continue until 31st March 2027, with an option for the Commissioner to extend for 24 months until 31 March 2029.

The award criteria is as stated below:

Integration, collaboration and service sustainability - 20.00%

Improving access, reducing health inequalities and facilitating choice - 45.00%

Quality and Innovation - 25.00%

Social Value - 10.00%

Value - Pass / Fail

Please note the deadline for responses to the ITT is 12:00PM (Mid-Day) on Friday 14th March 2025.

II.2.5) Award criteria

Price is not the only award criterion and all criteria are stated only in the procurement documents

II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Start date

1 May 2025

End date

31 March 2029

This contract is subject to renewal

No

II.2.10) Information about variants

Variants will be accepted: No

II.2.11) Information about options

Options: Yes

Description of options

Services will commence in May 2025 and will continue until 31st March 2027, with an option for the Commissioner to extend for 24 months until 31 March 2029.

II.2.13) Information about European Union Funds

The procurement is related to a project and/or programme financed by European Union funds: No

II.2) Description

II.2.1) Title

Lot 2: NHS Leicester, Leicestershire, & Rutland ICB

Lot No

2

II.2.2) Additional CPV code(s)

- 85100000 - Health services

II.2.3) Place of performance

NUTS codes

- UKF2 - Leicestershire, Rutland and Northamptonshire

II.2.4) Description of the procurement

NHS Arden and Greater East Midlands Commissioning Support Unit (AGCSU) on behalf of NHS England (NHSE) (The Commissioner) would like to notify the market of an opportunity to provide Community Pharmacy RSV and Pertussis Vaccination Enhanced Service within the Midlands Region.

Respiratory Syncytial Virus (RSV) is a virus that for most people causes a mild respiratory illness, but can be more serious for those, including older adults and infants, who are at risk of more severe respiratory disease. Following the Joint Committee on Vaccination and Immunisation (JCVI) recommendation, the Commissioner will commission from September 2024:

- an adult programme (predominately to be commissioned through general practice); and
- an infant programme provided as vaccination during pregnancy (predominantly to be commissioned through NHS Trusts).

In addition, where there are areas of identified additional need, the Commissioner will commission community pharmacy to provide additional capacity and increased access to supplement the core provision of these two programmes.

Pertussis (whooping cough) is a respiratory disease that is caused by the *Bordetella pertussis* bacterium. Pertussis can cause serious and life-threatening complications including pneumonia, difficulty in breathing (apnoea) and seizures. Pertussis most commonly affects infants, and very young infants are at highest risk of serious complications, of needing admission to hospital or of dying.

Pregnant women are eligible for the Pertussis vaccine from 16 weeks pregnancy, although the optimal window for protection is between 20 and 32 weeks of pregnancy. Commissioners have commissioned general practice and NHS trusts to deliver the Pertussis vaccination programme for pregnant women.

In addition, where there are areas of identified additional need, the Commissioner will commission community pharmacy to provide the Pertussis vaccination programme opportunistically to pregnant women to supplement the core service provision.

This Procurement Process is for the service provision in the Midlands Region where up to 66 sites from multiple potential Suppliers will be selected to provide the Services from May 2025. The 66 successful sites will be in three ICBs within the Midlands Region, with

22 sites allocated per lot to allow the Commissioner to ensure an even geographical spread. Should fewer than 22 sites be awarded to a Lot, up to 4 additional sites may be awarded under alternative Lot(s) at the Commissioners discretion. The ICB's included in this procurement are NHS Black Country ICB, NHS Leicester, Leicestershire, & Rutland ICB & NHS Birmingham and Solihull ICB.

The value of the service provision resulting from this Procurement Process will be an Item of Service (IoS) fee of £9.58 for the administration of each RSV and pertussis vaccine to each eligible patient.

The number of eligible patients, and therefore the likely activity level, could change as a result of factors beyond the Commissioner's control such as an increase or decrease in population of the local area, closure or merger of other nearby NHS health organisations, or patient.

Services will commence in May 2025 and will continue until 31st March 2027, with an option for the Commissioner to extend for 24 months until 31 March 2029.

The award criteria is as stated below:

Integration, collaboration and service sustainability - 20.00%

Improving access, reducing health inequalities and facilitating choice - 45.00%

Quality and Innovation - 25.00%

Social Value - 10.00%

Value - Pass / Fail

Please note the deadline for responses to the ITT is 12:00PM (Mid-Day) on Friday 14th March 2025.

II.2.5) Award criteria

Price is not the only award criterion and all criteria are stated only in the procurement documents

II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Start date

1 May 2025

End date

31 March 2029

This contract is subject to renewal

No

II.2.10) Information about variants

Variants will be accepted: No

II.2.11) Information about options

Options: Yes

Description of options

Services will commence in May 2025 and will continue until 31st March 2027, with an option for the Commissioner to extend for 24 months until 31 March 2029.

II.2.13) Information about European Union Funds

The procurement is related to a project and/or programme financed by European Union funds: No

II.2) Description

II.2.1) Title

Lot 3: NHS Birmingham and Solihull ICB

Lot No

3

II.2.2) Additional CPV code(s)

- 85100000 - Health services

II.2.3) Place of performance

NUTS codes

- UKG3 - West Midlands

II.2.4) Description of the procurement

NHS Arden and Greater East Midlands Commissioning Support Unit (AGCSU) on behalf of NHS England (NHSE) (The Commissioner) would like to notify the market of an opportunity to provide Community Pharmacy RSV and Pertussis Vaccination Enhanced

Service within the Midlands Region.

Respiratory Syncytial Virus (RSV) is a virus that for most people causes a mild respiratory illness, but can be more serious for those, including older adults and infants, who are at risk of more severe respiratory disease. Following the Joint Committee on Vaccination and Immunisation (JCVI) recommendation, the Commissioner will commission from September 2024:

- an adult programme (predominately to be commissioned through general practice); and
- an infant programme provided as vaccination during pregnancy (predominantly to be commissioned through NHS Trusts).

In addition, where there are areas of identified additional need, the Commissioner will commission community pharmacy to provide additional capacity and increased access to supplement the core provision of these two programmes.

Pertussis (whooping cough) is a respiratory disease that is caused by the *Bordetella pertussis* bacterium. Pertussis can cause serious and life-threatening complications including pneumonia, difficulty in breathing (apnoea) and seizures. Pertussis most commonly affects infants, and very young infants are at highest risk of serious complications, of needing admission to hospital or of dying.

Pregnant women are eligible for the Pertussis vaccine from 16 weeks pregnancy, although the optimal window for protection is between 20 and 32 weeks of pregnancy. Commissioners have commissioned general practice and NHS trusts to deliver the Pertussis vaccination programme for pregnant women.

In addition, where there are areas of identified additional need, the Commissioner will commission community pharmacy to provide the Pertussis vaccination programme opportunistically to pregnant women to supplement the core service provision.

This Procurement Process is for the service provision in the Midlands Region where up to 66 sites from multiple potential Suppliers will be selected to provide the Services from May 2025. The 66 successful sites will be in three ICBs within the Midlands Region, with 22 sites allocated per lot to allow the Commissioner to ensure an even geographical spread. Should fewer than 22 sites be awarded to a Lot, up to 4 additional sites may be awarded under alternative Lot(s) at the Commissioners discretion. The ICB's included in this procurement are NHS Black Country ICB, NHS Leicester, Leicestershire, & Rutland ICB & NHS Birmingham and Solihull ICB.

The value of the service provision resulting from this Procurement Process will be an Item of Service (IoS) fee of £9.58 for the administration of each RSV and pertussis vaccine to each eligible patient.

The number of eligible patients, and therefore the likely activity level, could change as a result of factors beyond the Commissioner's control such as an increase or decrease in population of the local area, closure or merger of other nearby NHS health organisations, or patient.

Services will commence in May 2025 and will continue until 31st March 2027, with an option for the Commissioner to extend for 24 months until 31 March 2029.

The award criteria is as stated below:

Integration, collaboration and service sustainability - 20.00%

Improving access, reducing health inequalities and facilitating choice - 45.00%

Quality and Innovation - 25.00%

Social Value - 10.00%

Value - Pass / Fail

Please note the deadline for responses to the ITT is 12:00PM (Mid-Day) on Friday 14th March 2025.

II.2.5) Award criteria

Price is not the only award criterion and all criteria are stated only in the procurement documents

II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Start date

1 May 2025

End date

31 March 2029

This contract is subject to renewal

No

II.2.10) Information about variants

Variants will be accepted: No

II.2.11) Information about options

Options: Yes

Description of options

Services will commence in May 2025 and will continue until 31st March 2027, with an option for the Commissioner to extend for 24 months until 31 March 2029.

II.2.13) Information about European Union Funds

The procurement is related to a project and/or programme financed by European Union funds: No

Section III. Legal, economic, financial and technical information

III.1) Conditions for participation

III.1.2) Economic and financial standing

Selection criteria as stated in the procurement documents

III.1.3) Technical and professional ability

Selection criteria as stated in the procurement documents

Section IV. Procedure

IV.1) Description

IV.1.1) Type of procedure

Open procedure

IV.1.8) Information about the Government Procurement Agreement (GPA)

The procurement is covered by the Government Procurement Agreement: Yes

IV.2) Administrative information

IV.2.2) Time limit for receipt of tenders or requests to participate

Date

14 March 2025

Local time

12:00pm

IV.2.4) Languages in which tenders or requests to participate may be submitted

English

IV.2.6) Minimum time frame during which the tenderer must maintain the tender

Duration in months: 6 (from the date stated for receipt of tender)

IV.2.7) Conditions for opening of tenders

Date

14 March 2025

Local time

1:00pm

Section VI. Complementary information

VI.1) Information about recurrence

This is a recurrent procurement: No

VI.3) Additional information

This is a Provider Selection Regime (PSR) Contract Notice. The awarding of this contract is subject to the Health Care Services (Provider Selection Regime) Regulations 2023. For the avoidance of doubt, the provisions of the Public Contracts Regulations 2015 do not apply to this award.

The Contracting Authority will be using an eTendering system for this procurement exercise.

Further information and the ITT documentation can be found via the 'Live Opportunities' list on the e-tendering system at the following link:

<https://health-family-contract-search.secure.force.com/?searchtype=Projects>

You can also register your interest via this page. You can search for the opportunity by entering the following contract reference: C342898 - COMP: Community Pharmacy RSV and Pertussis Vaccination Enhanced Service

Neither the publication of this notice nor the employment of any particular terminology nor any other indication shall be taken to mean that the Contracting Authority intends to hold itself bound by any of the Regulations.

The award criteria is as stated below:

Integration, collaboration and service sustainability - 20.00%

Improving access, reducing health inequalities and facilitating choice - 45.00%

Quality and Innovation - 25.00%

Social Value - 10.00%

Value - Pass / Fail

Please see published procurement documentation for further details. All relevant information on the stages of evaluation are stated within the ITT documentation suite.

VI.4) Procedures for review

VI.4.1) Review body

NHS England

Wellington House, 133-135 Waterloo Rd

London

SE1 8UG

Country

United Kingdom

Internet address

<https://www.england.nhs.uk/>

VI.4.2) Body responsible for mediation procedures

NHS Arden and GEM CSU

St John's House, East Street

Leicester

LE1 6NB

Country

United Kingdom

Internet address

<https://www.ardengemcsu.nhs.uk/>